PAI-1 and TAFI in inflammatory bowel disease: The yin and yang of the fibrinolytic system

Silvio Danese, Alfredo Papa

Research output: Contribution to journalArticlepeer-review


In both Crohn's disease and ulcerative colitis, the two major forms of inflammatory bowel disease (IBD), an increased risk of thrombotic events has been demonstrated. Pathogenesis of thrombosis is multifactorial as various primary coagulation system abnormalities other than acquired factors have been reported. The fibrinolytic system has been widely investigated in IBD. Most of the available data report an imbalance in fibrinolytic capacity with a tendency toward a hypofibrinolytic state. Plasma thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 are fundamental inhibitors of the fibrinolytic process and are also considered to be acute-phase reactants. Recent studies have shown an imbalance of plasminogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitor, suggesting that these molecules might contribute to thromboembolic events in both forms of IBD.

Original languageEnglish
Pages (from-to)826-828
Number of pages3
JournalEuropean Journal of Gastroenterology and Hepatology
Issue number9
Publication statusPublished - Sep 2008


  • Fibrinolysis
  • Inflammatory bowel disease
  • Plasminogen activator inhibitor-1
  • Thrombin-activatable fibrinolysis inhibitor

ASJC Scopus subject areas

  • Gastroenterology
  • Hepatology


Dive into the research topics of 'PAI-1 and TAFI in inflammatory bowel disease: The yin and yang of the fibrinolytic system'. Together they form a unique fingerprint.

Cite this